secwatch.observer — SEC 8-K summary
======================================

Issuer:     TREACE MEDICAL CONCEPTS, INC. (TMCI)
CIK:        0001630627
Form:       8-K
Filed at:   2026-08-07T11:10:15+00:00
Accession:  0001630627-26-000017
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Treace Q2 2026 revenue $45.4M (-4% YoY), net loss $15.9M, raises FY guidance
----------------------------------------------------------------------------

- Q2 2026 revenue $45.4M vs $47.4M in Q2 2025 (-4%); net loss $(15.9)M or $(0.24)/share.
- Adjusted EBITDA loss $(3.5)M, improved from $(3.6)M; gross margin 78.5% vs 79.7%.
- Cash usage cut 57% YoY; cash and securities $45.6M at June 30, 2026.
- FY 2026 revenue guidance raised to $204-212M (from $202-212M); EBITDA loss narrowed to $3-5M.
- New products: SuperBite Screw System launched, HyperPlate XM first case; 40% of surgeons use new bunion systems.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1630627/000163062726000017/0001630627-26-000017-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1630627/000163062726000017/tmci-20260807.htm
  HTML page:      https://secwatch.observer/filing/0001630627-26-000017

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer